Teva to Outline R&D Pipeline and Growth Strategy at November Event

  • Teva Pharmaceutical Industries Ltd. will host an R&D Day on November 11, 2026, in New York City.
  • The event will focus on Teva’s R&D pipeline and its near-term value-creation potential over the next five years.
  • Teva’s leadership will discuss its transformation into an innovative biopharma company through the Pivot to Growth strategy.
  • In-person attendance is by invitation only, with a live webcast and archived recording available.
  • Presentations will run from 8:30 a.m. to 12:30 p.m. Eastern Time.

Teva’s R&D Day comes as the company seeks to pivot from its traditional generics business to a more innovative biopharma model. The event will provide insights into how Teva plans to leverage its R&D pipeline to drive growth, a critical shift in an industry increasingly focused on high-value, differentiated therapies. The success of this strategy will hinge on Teva’s ability to execute on its pipeline and sustain profitability in a competitive market.

Pipeline Execution
How Teva’s R&D pipeline will translate into near-term value creation and sustainable growth.
Strategic Shift
Whether Teva’s Pivot to Growth strategy can successfully position it as a leading innovative biopharma company.
Market Positioning
The pace at which Teva can expand its innovative and biosimilar medicines portfolio to compete in the marketplace.